I believe leonlimab biggest role could be given at earlier stages to prevent metastatis to begin with and also helping stop recurrence after remission. Unfortunately those paths to approval I believe are very long, so they went with the fastest with helping stage 4. It will help but the earlier the better. Like the mice, at a very late stage, switching to leronlimab, 50% survived, there is some sort of curve and the earlier the patients is put on leronlimab, the better chance of survival. Hopefully, if it is proven in the metastatic setting, it will expand to more stages, especially stage 3.